ライフサイエンスコーパス: adrenergic-blocking agent

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ne-recommended medications (aspirin and beta-adrenergic blocking agents).

2 ing chronic heart failure patients with beta-adrenergic blocking agents.

3 h either alpha-2 adrenergic agonists or beta adrenergic blocking agents.

4 in, p < 0.0001) and more often received beta-adrenergic blocking agents (49% vs. 14%, p < 0.0001).

5 However, for the subset of patients on beta-adrenergic blocking agents after CABG, there was a trend

6 New medical treatments, including alpha-adrenergic blocking agents and 5 alpha-reductase inhibit

7 ng-term health outcomes associated with beta-adrenergic blocking agents and diltiazem treatment for u

8 mean age 57 years) who were not taking beta-adrenergic blocking agents and were referred for symptom

9 l Question: Does nurse-led titration of beta-adrenergic blocking agents, angiotensin-converting enzym

10 The use of aspirin, beta-adrenergic blocking agents, angiotensin-converting enzym

11 s with such capability when aspirin and beta-adrenergic blocking agents are given appropriately and t

12 Beta-adrenergic blocking agents are used in most patients for

13 eatments for patients with AMI, such as beta-adrenergic blocking agents, aspirin and immediate reperf

14 or the use of concomitant medications (beta-adrenergic blocking agents, calcium channel blocking age

15 of several studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a sign

16 The short-acting beta1-selective adrenergic blocking agent, esmolol, was administrated du

17 lude initial therapy with a diuretic or beta-adrenergic blocking agent, for which reductions in morbi

18 Chronic treatment with beta-adrenergic blocking agents has been shown to improve lef

19 Beta-adrenergic blocking agents have been revalidated in rece

20 re also more likely to receive aspirin, beta-adrenergic blocking agents, heparin and nitrates (all p

21 edications such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comprehen

22 in cardiomyopathy patients treated with beta-adrenergic blocking agents is controversial.

23 as designed to examine the effects of a beta-adrenergic blocking agent on the ischemic response to do

24 -converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process.

25 with stable angina pectoris receiving a beta-adrenergic blocking agent or calcium antagonist, or both

26 ment with either timolol, a nonspecific beta adrenergic blocking agent, or with para-aminoclonidine,

27 ns: patients with first MI, patients on beta-adrenergic blocking agents, patients with LVEF < or =30%

28 Phentolamine, an alpha-adrenergic blocking agent, prevents the C75-induced incr

29 group 1 patients had significantly less beta-adrenergic blocking agent use and higher ejection fracti

30 nalysis was performed to assess whether beta-adrenergic blocking agent use is associated with reduced

31 ltivariate analysis, the association of beta-adrenergic blocking agent use with reduced mortality rem

32 ts; After adjusting for age, gender and beta-adrenergic blocking agent use, multiple logistic regress

33 sely to prior myocardial infarction and beta-adrenergic blocking agent use.

34 Beta-adrenergic blocking agents were administered concurrentl

35 tensin-converting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the pati

36 A short-acting beta1-selective adrenergic blocking agent, when administered during card

37 Sotalol, a beta-adrenergic blocking agent with class III antiarrhythmic

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。